Altogether, the further optimization of CARs towards higher efficacy and safety and the adoption of poly-specific approaches unveil new opportunities for expanding the therapeutic window and clinical applicability of CD38-specific products in multiple myeloma. The gene discussed is CD38; the disease is plasma cell myeloma.